and Human Services
9000 Rockville Pike
Bethesda, Maryland 20892
CANCER EDUCATION GRANT PROGRAM
RELEASE DATE: April 3, 2003
PA NUMBER: PAR-03-093
EXPIRATION DATE: February 2, 2005
National Cancer Institute (NCI)
(http://www.nci.nih.gov/)
CATALOG OF FEDERAL DOMESTIC ASSISTANCE NUMBER (S): 93.398
This Program Announcement (PAR) replaces PAR-00-033, which was published in
the NIH Guide on December 22, 1999.
THIS PAR CONTAINS THE FOLLOWING INFORMATION
o Purpose of the PAR
o Objectives of the Cancer Education Grant Program
o Mechanism of Support
o Eligible Institutions
o Individuals Eligible to Become Principal Investigators
o Special Requirements
o Where to Send Inquiries
o Submitting an Application
o Peer Review Process
o Review Criteria
o Award Criteria
o Required Federal Citations
PURPOSE
The purpose of the Cancer Education Grant Program (CEGP) is to support the
development and dissemination of innovative education approaches, methods and
tools that ultimately will have an impact on reducing cancer incidence,
mortality, morbidity, and improving the quality of life of cancer survivors.
OBJECTIVES OF THE CANCER EDUCATION GRANT PROGRAM
Background: The Cancer Education Grant Program, which employs the R25 grant
mechanism, was reorganized in 1993 to provide institutions a wide range of
opportunities to develop and sustain unique, innovative, primarily
curriculum-driven programs that focus on various cancer education activities
as opposed to the conduct of biomedical research. The development of more
refined, more effective education methods and tools for biomedical
scientists, health care professionals, students and the lay community are
essential components of the overall mission of the National Cancer Institute
to reduce cancer incidence and mortality. Unlike typical research grants,
which test research outcomes using experimental controls, R25 grants are
experiments in new educational approaches that determine their success or
failure through the application of carefully designed evaluation plans.
Objectives: The Cancer Education Grant Program of the National Cancer
Institute is a flexible, primarily curriculum-driven program aimed at
developing and sustaining innovative educational approaches that ultimately
will have an impact on reducing cancer incidence, morbidity, mortality, and
on improving the quality of life of cancer survivors. The CEGP invites
investigator-initiated R25 grant applications that pursue a wide range of
objectives from short courses, national forums, seminars, and/or hands-on
workshops designed to educate scientists, health care professionals, students
and the lay community; to the design, development and evaluation of new
curricula of special significance to cancer in educational institutions;
structured short-term didactic and research experiences designed to motivate
high school, college and medical, dental and other health professional
students to pursue careers in cancer research; to the development and
evaluation of new educational methods and tools directed at special
audiences (e.g., minorities and underserved populations); to web-based and
virtual approaches to cancer education. The ranges of possibilities for this
award are unlimited; as long as they focus on new approaches to cancer
education, can be disseminated effectively, and potentially have wide
applicability.
Because of the wide spectrum of possible ways to use the Cancer Education
Program, all applicants are urged to contact NCI program staff before
preparing an application (see WHERE TO SEND INQUIRIES)
MECHANISM OF SUPPORT
The NCI Cancer Education Grant Program uses the NIH R25 grant mechanism. As
an applicant, you will be solely responsible for planning, directing, and
executing the proposed project.
New applicants may request up to five years of support in a single grant
period in order to develop or maintain a specific education program. The
maximum support in direct costs per year is $300,000. Applications exceeding
this cap will be returned unless specific permission has been obtained in
writing from the NCI program staff. Facilities and administration (F & A)
costs, which formerly were called indirect costs, will be reimbursed at 8
percent of the modified direct costs. It is important to note that
subcontracts are also restricted to the same 8% reimbursement of modified
direct costs. For purposes of determining the cap, indirect costs included
in a subcontract will not count against the direct cost cap.
Independently from the amount requested, this PAR does not use a modular
budget. A complete and detailed budget should be submitted. This PAR is not
subject to "Just-in-time" application procedures or to the Streamlined Non-
competing Application Process (SNAP). The R25 remains under "Expanded
Authorities" except that carryover of funds from one fiscal year to the next
requires approval by the NCI.
In general, allowable costs must be consistent with NIH policy and the
recommendations of peer reviewers. These costs include but are not limited
to the following: personnel costs, supplies, student compensation (when
appropriate), student subsistence allowance (e.g., partial costs for meals
and/or for lodging, when appropriate), other student costs (e.g., tuitions,
travel expenses, when appropriate), consultant costs, equipment, travel,
subcontractual costs (as long as subcontracts are not awarded with a higher
indirect cost than 8%), and other expenses. It is recommended that potential
applicants consult NCI staff if there are any questions regarding allowable
costs.
Because the CEGP is primarily intended to support studies that can be
completed within five years and sustained afterwards with other resources
(e.g., institutional, community), all applications submitted as competing
renewals must receive prior consultation and written approval from NCI
program staff. Programs with reasonable justification, such as short-term
cancer research and educational experiences designed to motivate individuals
to pursue cancer research careers (e.g., medical students) or educational
programs for disadvantaged, underserved and minority populations that
experience higher cancer incidence and mortality, are generally approved for
submission.
ELIGIBLE INSTITUTIONS
o Domestic (See below for exceptions)
o For Profit or non-profit organizations and professional societies
o Public or private institutions, such as universities, colleges, hospitals,
and laboratories
o Units of State and local governments
o Eligible agencies of the Federal government
o Faith-based or community-based organizations
Eligibility to apply for a grant is normally limited to domestic
institutions. Under special circumstances foreign institutions may request a
formal waiver of this requirement after consulting with and receiving written
approval from NCI.
INDIVIDUALS ELIGIBLE TO BECOME PRINCIPAL INVESTIGATORS
The Program Leader/Principal Investigator must be an expert
educator/investigator in the proposed field and be able to provide both
administrative and scientific leadership to the Program. Racial/ethnic
minority individuals, women, and persons with disabilities are encouraged to
apply as principal investigators.
SPECIAL REQUIREMENTS
R25 grant applications submitted under this announcement may not be used to
conduct traditional research or training.
The NCI requires that R25 grant applications submitted in response to this
announcement contain two special sections: (1) an "Evaluation Plan" that
clearly denotes how the proposed education program will be evaluated for
success or failure based on its purpose and objectives. One of the evaluation
criteria should focus on the degree of applicability the proposed program
will have to other educational institutions, geographic areas and/or
different populations; and (2) a "Dissemination Plan" that clearly indicates
how the applicant will communicate and make available the results of the
study (e.g., publications, presentations) to the potential user community
(e.g., cancer centers, universities and other educational institutions,
professional societies, communities etc.). Applications submitted without
these two sections will not receive further consideration.
When the application is designed for completion within a five year period or
less using Federal resources AND is expected to continue without additional
Federal support, the applicant institution must include a plan, with
appropriate commitment of resources, to continue the effort after the period
of grant support ends. Examples of these kinds of studies might be
curriculum development within the institution in areas of critical importance
to cancer education (e.g., nutrition, pain management) or efforts directed to
the community (e.g., outreach programs to the lay public, educational
programs for community health care professionals).
A final progress report, invention statement, and Financial Status Report are
required upon termination of an award.
Evaluation from NCI: In carrying out its stewardship of human resource
related programs, the NCI may request information essential to an assessment
of the effectiveness of this program. Accordingly, recipients are hereby
notified, that they may be contacted after the completion of this award for
periodic updates on various aspects of the educational program including, but
not limited to, achievement obtained through the program, trainee
accomplishments, publications, dissemination, honors and awards, professional
activities, and other information helpful in evaluating the impact of the
program.
WHERE TO SEND INQUIRIES
We encourage your inquiries concerning this PAR and welcome the opportunity
to answer questions from potential applicants. Inquiries may fall into three
areas: scientific/research, peer review, and financial or grants management
issues:
o Direct your questions about scientific/research issues to:
Dr. Maria Agelli
National Cancer Institute
Cancer Training Branch
6116 Executive Boulevard, Suite 700
Bethesda, MD 20892
Telephone: (301) 496-8580
Email: ma215e@nih.gov
o Direct your questions about peer review issues to:
Referral Officer
National Cancer Institute
Division of Extramural Activities
6116 Executive Boulevard, Room 8041, MSC 8329
Bethesda, MD 20892-8329
Telephone: (301) 496-3428
FAX: (301) 402-0275
Email: ncirefof@dea.nci.nih.gov
o Direct your questions about financial or grants management matters to:
Ms. Catherine Blount
National Cancer Institute
Grants Administration Branch
6120 Executive Blvd.
Room EPS 243
Bethesda, MD 20892
Phone: (301) 496-3179
Fax: (301) 496-8601
e-mail: blountc@mail.nih.gov
SUBMITTING AN APPLICATION
Applications should be prepared using the PHS 398 research grant application
instructions and forms (rev. 5/2001). The CEGP allows for a wide range of
approaches and topics but applicants are expected to generally follow the
instructions and Table of Contents provided in the PHS 398-application kit
with respect to the organization of the application. The PHS 398 is
available at http://grants.nih.gov/grants/funding/phs398/phs398.html in an
interactive format. For further assistance contact GrantsInfo, Telephone
(301) 435-0714, Email: GrantsInfo@nih.gov.
The instructions in the Form PHS 398 do not fully apply to the special needs
of this grant application. Therefore, please follow the modified
instructions below in preparing an application for an NCI Cancer Education
Grant (R25) Program. These instructions have been adapted to accommodate the
Form PHS 398 and the special needs of the CEGP:
1. Face Page: Use Form Page 1 of the Form PHS 398. On Line 1, include the
title that best represents the nature of the training program. On Line 2,
provide the number of this Program Announcement beginning with PAR-03-093,
and the title "Cancer Education Grant Program (R25)".
2. Description/ Performance site(s)/ Key personnel (Form Page 2 of Form PHS
398): Under Performance Sites include "Consortium/ Contractual Arrangements"
with a description of plans for collaborating with other institutions for the
purpose of exchange and sharing of resources including faculty, equipment and
facilities. If multiple sites are to be used, the applicant institution must
be one of those sites and a strong justification must be provided for
inclusion of the other sites in the proposed education program.
3. Resources: Use the Resource Format page and describe the educational
environment. Include in this description the facilities, laboratories,
participating departments, and any other resources to be used in the conduct
of the proposed program. Use continuation pages as necessary.
4. Research Plan
o Retitle Part C. "Preliminary Activities" and include if applicable.
This section should contain information on the steps that have led to the
proposed program.
o Retitle Part D of this section "Cancer Education Program Plan". The
information provided in this section should be organized as follows:
a. Program Direction. Describe the qualifications and role of the PI to
provide scientific and administrative leadership and coordination of the
Program and the plans for management of the program.
b. Program Faculty/ Staff. Describe the experience and responsibilities of
the faculty and staff.
c. Proposed Cancer Education Program. Briefly describe the background,
purpose and objectives of the Program. Provide programmatic detail on
special activities proposed (e.g., courses, curricula, workshops, etc.) as
well as evidence of institutional and community commitment and support of the
proposed program. Where appropriate, provide information on the proposed
participants, and the plans for recruiting and retaining participants,
including individuals from underrepresented racial/ethnic groups, women and
persons with disabilities.
d. Cancer Education Evaluation Plan. Provide a plan for evaluating the
success of the program in achieving its goals and objectives. Applications
that do not have an adequate evaluation plan will be considered non-
responsive to this program announcement.
e. Dissemination Plan. Provide a plan for disseminating the knowledge
acquired from the education program. The plan should include a description
of the venues that will be used and the populations, institutions,
organizations, etc., that will be targeted for receiving information about
the program. Applications that do not have an adequate dissemination plan
will be considered non-responsive to this program announcement.
f. Statement of Institutional Commitment. Where appropriate, evidence of
institutional commitment and plans to continue funding the educational
program after the period of grant support ends.
5. Human Subjects. The revised policy for IRB review of human subjects
protocols in grant applications can be found at the following URL:
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-031.html
APPLICATION RECEIPT DATES: Applications submitted in response to this program
announcement will be accepted at the standard application deadlines, which
are available at http://grants.nih.gov/grants/dates.htm. Application
deadlines are also indicated in the PHS 398 application kit.
SENDING AN APPLICATION TO THE NIH: Submit a signed, typewritten original of
the application, including the checklist, and three signed photocopies in one
package to:
Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710
Bethesda, MD 20817 (for express/courier service)
To expedite the review process, which will be conducted by the NCI, two
additional copies must be sent to:
Referral Officer
Division of Extramural Activities
National Cancer Institute
6116 Executive Boulevard, Room 8041, MSC 8329
Bethesda, MD 20892-8329
Rockville, MD 20852 (for express/courier service)
APPLICATIONS HAND-DELIVERED BY INDIVIDUALS TO THE NATIONAL CANCER INSTITUTE
WILL NO LONGER BE ACCEPTED. This policy does not apply to courier deliveries
(i.e. FEDEX, UPS, DHL, etc.) (http://grants.nih.gov/grants/guide/notice-files/
NOT-CA-02-002.html) This change in practice is effective immediately.
This policy is similar to and consistent with the policy for applications
addressed to Centers for Scientific Review as published in the NIH Guide
Notice http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-012.html.
APPLICATION PROCESSING: Applications must be received by the date(s) listed
on the first page of this PAR. The CSR will not accept any application in
response to this PAR that is essentially the same as one currently pending
initial review unless the applicant withdraws the pending application. The
CSR will not accept any application that is essentially the same as one
already reviewed. This does not preclude the submission of a substantial
revision of an application already reviewed, but such application must
include an Introduction addressing the previous critique
Although there is no immediate acknowledgement of the receipt of an
application, applicants are generally notified of the review and funding
assignment within 8 weeks.
PEER REVIEW PROCESS
Upon receipt, applications will be reviewed for completeness by the CSR and
for adherence to the guidelines of this PAR by the NCI program staff.
Applications not adhering to the guidelines of this PAR, and those
applications that are incomplete as determined by CSR or by NCI program
staff, will not receive further consideration. Applications that are
complete and adhere to the guidelines of this PAR will be evaluated for
scientific and technical merit by an appropriate peer review group convened
by the Division of Extramural Activities of the NCI in accordance with the
review criteria stated below.
As part of the initial merit review, all applications will:
o Receive a written critique
o Undergo a process in which only those applications deemed to have the
highest scientific merit, generally the top half of the applications under
review, will be discussed and assigned a priority score
o Those that receive a priority score will undergo a second level review by
the National Cancer Advisory Board.
REVIEW CRITERIA
The goals of NIH-supported research are to advance our understanding of
biological systems, improve the control of disease, and enhance health. In
the written comments, reviewers will be asked to discuss the following
aspects of your application in order to judge the likelihood that the
proposed research will have a substantial impact on the pursuit of these
goals:
1. Novelty and significance of the education program to cancer research
and/or to the reduction of cancer incidence, morbidity, and mortality and to
the improvement of quality of life of cancer survivors.
2. Quality of the program leader (principal investigator) in terms of past
track record of achievement and experience to provide direction,
coordination, and administration of the Program.
3. Quality of the key personnel and/or faculty who will participate in the
Program.
4. The overall quality and adequacy of the design of the Program to achieve
its short-term and long-term objectives.
5. Where appropriate, adequacy of plans for recruitment and retention of
program participants, including participants from underrepresented
racial/ethnic groups, women and persons with disabilities.
6. Degree of applicability and portability of the proposed program to other
institutions, geographic areas, and populations.
7. Adequacy of the required "Evaluation Plan" to assess the effectiveness of
the Program in achieving its objectives.
8. Adequacy of the "Dissemination Plan" to communicate and make available
the results of the study through publications in professional journals,
publications/presentations at national and international meetings, and
internet websites; and to reach the potential user community effectively
(e.g., cancer centers, universities and other educational institutions,
professional societies, hospitals, other educators).
9. When the program is expected to continue without additional Federal
Resources, sufficiency of the applicant institution's plan and commitment of
resources to continue the Program after the period of Federal grant support
ends.
10. The following review criteria apply only to proposed education programs
that involve short-term experiences in a research environment and which are
renewable:
a. Quality of the proposed short-term education program, taking into account
the quality (and track records, if a renewal application) of the program
design, and of the educational environment; the commitment of the
participating faculty; the availability of research support, inclusion of
information related to new, rapidly developing topics/fields in biomedical
research.
b. Access to candidates for short-term experiences and the ability to
recruit high quality individuals from the applicant institution or other
schools. Evaluate the track record for a renewal application.
c. Characteristics of the educational program that might be expected to
persuade short-term participants to consider cancer research careers.
Evaluate the track record for a renewal application.
d. Success in attracting students back for repeated short-term appointments.
e. Success in recruiting under-represented minorities.
f. Plan to follow former participants and to assess the effect of such a
program on their research careers. Evaluate the track record for a renewal
application.
11. For all other renewal applications, the track record of productivity.
ADDITIONAL REVIEW CRITERIA: In addition to the above criteria, the initial
review group will also evaluate:
PROTECTION OF HUMAN SUBJECTS FROM RESEARCH RISK: The involvement of human
subjects and protections from research risk relating to their participation
in the proposed research will be assessed. (See criteria included in the
section on Federal Citations, below).
INCLUSION OF WOMEN, MINORITIES AND CHILDREN IN RESEARCH: The adequacy of
plans to include subjects from both genders, all racial and ethnic groups
(and subgroups), and children as appropriate for the scientific goals of the
research will be assessed. Plans for the recruitment and retention of
subjects will also be evaluated. (See Inclusion Criteria in the sections on
Federal Citations, below).
CARE AND USE OF VERTEBRATE ANIMALS IN RESEARCH: If vertebrate animals are to
be used in the project, the five items described under Section f of the PHS
398 research grant application instructions (rev. 5/2001) will be assessed.
ADDITIONAL CONSIDERATIONS
BUDGET: Appropriateness of the budget and duration of the support needed to
achieve the stated goals and objectives.
AWARD CRITERIA
Applications submitted in response to a PAR will compete for available funds
with all other recommended applications. The following will be considered in
making funding decisions:
o Educational merit of the proposed project as determined by peer review
o Availability of funds
o Relevance to program priorities
REQUIRED FEDERAL CITATIONS
HUMAN SUBJECTS PROTECTION: Federal regulations (45CFR46) require that
applications and proposals involving human subjects must be evaluated with
reference to the risks to the subjects, the adequacy of protection against
these risks, the potential benefits of the research to the subjects and
others, and the importance of the knowledge gained or to be gained.
INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH: It is the policy of
the NIH that women and members of minority groups and their sub-populations
must be included in all NIH-supported clinical research projects unless a
clear and compelling justification is provided indicating that inclusion is
inappropriate with respect to the health of the subjects or the purpose of
the research. This policy results from the NIH Revitalization Act of 1993
(Section 492B of Public Law 103-43).
All investigators proposing clinical research should read the AMENDMENT "NIH
Guidelines for Inclusion of Women and Minorities as Subjects in Clinical
Research - Amended, October, 2001," published in the NIH Guide for Grants and
Contracts on October 9, 2001 (http://grants.nih.gov/grants/guide/notice-files/
NOT-OD-02-001.html); a complete copy of the updated Guidelines are
available at http://grants.nih.gov/grants/funding/women_min/guidelines_
amended_10_2001.htm.The amended policy incorporates: the use of an NIH
definition of clinical research; updated racial and ethnic categories in
compliance with the new OMB standards; clarification of language governing
NIH-defined Phase III clinical trials consistent with the new PHS Form 398;
and updated roles and responsibilities of NIH staff and the extramural
community. The policy continues to require for all NIH-defined Phase III
clinical trials that: a) all applications or proposals and/or protocols must
provide a description of plans to conduct analyses, as appropriate, to address
differences by sex/gender and/or racial/ethnic groups, including subgroups if
applicable; and b) investigators must report annual accrual and progress in
conducting analyses, as appropriate, by sex/gender and/or racial/ethnic group
differences.
INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS:
The NIH maintains a policy that children (i.e., individuals under the age of
21) must be included in all human subjects research, conducted or supported
by the NIH, unless there are scientific and ethical reasons not to include
them. This policy applies to all initial (Type 1) applications submitted for
receipt dates after October 1, 1998.
All investigators proposing research involving human subjects should read the
"NIH Policy and Guidelines" on the inclusion of children as participants in
research involving human subjects that is available at
http://grants.nih.gov/grants/funding/children/children.htm.
REQUIRED EDUCATION ON THE PROTECTION OF HUMAN SUBJECT PARTICIPANTS: NIH
policy requires education on the protection of human subject participants for
all investigators submitting NIH proposals for research involving human
subjects. You will find this policy announcement in the NIH Guide for Grants
and Contracts Announcement, dated June 5, 2000, at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html. A
continuing education program in the protection of human participants in
research in now available online at: http://cme.nci.nih.gov/.
HUMAN EMBRYONIC STEM CELLS (hESC): Criteria for federal funding of research
on hESCs can be found at http://grants.nih.gov/grants/stem_cells.htm and at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html. Guidance
for investigators and institutional review boards regarding research
involving human embryonic stem cells, germ cells, and stem cell-derived test
articles can be found at http://grants.nih.gov/grants/guide/notice-files/
NOT-OD-02-044.html. Only research using hESC lines that are registered in
the NIH Human Embryonic Stem Cell Registry will be eligible for Federal funding
(see http://escr.nih.gov). It is the
responsibility of the applicant to provide the official NIH identifier(s)for
the hESC line(s) to be used in the proposed research. Applications that do
not provide this information will be returned without review.
PUBLIC ACCESS TO RESEARCH DATA THROUGH THE FREEDOM OF INFORMATION ACT: The
Office of Management and Budget (OMB) Circular A-110 has been revised to
provide public access to research data through the Freedom of Information Act
(FOIA) under some circumstances. Data that are (1) first produced in a
project that is supported in whole or in part with Federal funds and (2)
cited publicly and officially by a Federal agency in support of an action
that has the force and effect of law (i.e., a regulation) may be accessed
through FOIA. It is important for applicants to understand the basic scope
of this amendment. NIH has provided guidance at
http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm.
Applicants may wish to place data collected under this PAR in a public
archive, which can provide protections for the data and manage the
distribution for an indefinite period of time. If so, the application should
include a description of the archiving plan in the study design and include
information about this in the budget justification section of the
application. In addition, applicants should think about how to structure
informed consent statements and other human subjects procedures given the
potential for wider use of data collected under this award.
STANDARDS FOR PRIVACY OF INDIVIDUALLY IDENTIFIABLE HEALTH INFORMATION: The
Department of Health and Human Services (DHHS) issued final modification to
the "Standards for Privacy of Individually Identifiable Health Information",
the "Privacy Rule," on August 14, 2002. The Privacy Rule is a federal
regulation under the Health Insurance Portability and Accountability Act
(HIPAA) of 1996 that governs the protection of individually identifiable
health information, and is administered and enforced by the DHHS Office for
Civil Rights (OCR). Those who must comply with the Privacy Rule (classified
under the Rule as "covered entities") must do so by April 14, 2003 (with the
exception of small health plans which have an extra year to comply).
Decisions about applicability and implementation of the Privacy Rule reside
with the researcher and his/her institution. The OCR website
(http://www.hhs.gov/ocr/) provides information on the Privacy Rule, including
a complete Regulation Text and a set of decision tools on "Am I a covered
entity?" Information on the impact of the HIPAA Privacy Rule on NIH
processes involving the review, funding, and progress monitoring of grants,
cooperative agreements, and research contracts can be found at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.
URLs IN NIH GRANT APPLICATIONS OR APPENDICES: All applications and proposals
for NIH funding must be self-contained within specified page limitations.
Unless otherwise specified in an NIH solicitation, Internet addresses (URLs)
should not be used to provide information necessary to the review because
reviewers are under no obligation to view the Internet sites. Furthermore,
we caution reviewers that their anonymity may be compromised when they
directly access an Internet site.
HEALTHY PEOPLE 2010: The Public Health Service (PHS) is committed to
achieving the health promotion and disease prevention objectives of "Healthy
People 2010," a PHS-led national activity for setting priority areas. This
PAR, Cancer Education Grant Program, is related to the priority area of
cancer education and community–based programs. Potential applicants may
obtain a copy of "Healthy People 2010" at
http://www.health.gov/healthypeople/.
AUTHORITY AND REGULATIONS: This program is described in the Catalog of
Federal Domestic Assistance No. 93.398 at http://www.cfda.gov/, and is not
subject to the intergovernmental review requirements of Executive Order 12372
or Health Systems Agency review. Awards are made under authorization of
Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241
and 284) and administered under NIH grants policies described at
http://grants.nih.gov/grants/policy/policy.htm and under Federal Regulations
42 CFR 52 and 45 CFR Parts 74 and 92.
The PHS strongly encourages all grant recipients to provide a smoke-free
workplace and discourage the use of all tobacco products. In addition,
Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in
certain facilities (or in some cases, any portion of a facility) in which
regular or routine education, library, day care, health care, or early
childhood development services are provided to children. This is consistent
with the PHS mission to protect and advance the physical and mental health of
the American people.
Return to NIH Guide Main Index
|
|
Department of Health and Human Services |
|
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |